ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials

BACKGROUND: The advantages of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) in reducing risk of cardiovascular events (CVEs) and delaying end-stage kidney disease (ESKD) in patients with chronic kidney disease (CKD) is well-known. However, the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaru, He, Dandan, Zhang, Wei, Xing, Yue, Guo, Yipeng, Wang, Fuzhen, Jia, Junya, Yan, Tiekun, Liu, Youxia, Lin, Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242277/
https://www.ncbi.nlm.nih.gov/pubmed/32333236
http://dx.doi.org/10.1007/s40265-020-01290-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242277/
https://www.ncbi.nlm.nih.gov/pubmed/32333236
http://dx.doi.org/10.1007/s40265-020-01290-3

Ejemplares similares